Odense University Hospital
Odense University Hospital is recorded as a service provider in 92 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 92 trials · Latest update first
Targeting mTOR with everolimus and/or physical training for preventing postmenopausal bone loss and accelerated skeletal aging. The RapaLoad study.
Sponsor Odense University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/MOIRAI)
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
Glofitamab Combined With Pirtobrutinib in Relapsed/Refractory Patients with Mantle Cell Lymphoma Followed by an Extension in Treatment Naïve Patients (PLATO)
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease
Sponsor Odense University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
COPE-CP: The effect of Celecoxib on pain, quality of life, use of opioids, and inflammation in patients suffering from chronic pancreatitis: a multicenter randomized placebo-controlled, double-blinded clinical trial
Sponsor Odense University Hospital
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: a multicenter randomized clinical trial (MONITOR-RCT)
Sponsor Odense University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
B-NHL 2013 - Treatment protocol for mature aggressive B-cell lymphoma and leukemia in children and adolescents
Sponsor Universitaetsklinikum Muenster AöR
- Start (EU)
- Latest update
- Estimated end
LBL 2018 – International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma
Sponsor Universitaetsklinikum Muenster AöR
- Start (EU)
- Latest update
- Estimated end
A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy
Sponsor Odense University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
Oral laxatives after hip fracture surgery: A randomised controlled trial
Sponsor Odense University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
Early initiated vasopressor therapy vs. standard care of primarily fluid therapy in hypotensive patients in the emergency department – A pragmatic, multi-center, superiority, randomized controlled trial
Sponsor Odense University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
Propofol and Thiopental for intravenous induction in neonates: a dose-finding study (The ProThio Study)
Sponsor Odense University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized phase II study of gemcitabine versus reduced-dose combination chemotherapy in fragile patients with non-resectable pancreatic cancer
Sponsor Aalborg University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
DANOHCA: The Danish Out-of-Hospital Cardiac Arrest study
Sponsor Rigshospitalet
- Start (EU)
- Latest update
- Estimated end
- Not reported
Anticoagulant Therapy in patients with atrial fibrillation after surgical Left Atrial Appendage Closure: a randomized non-inferiority trial (the ATLAAC trial)
Sponsor Odense University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
The effect of oral Semaglutide on bone turnover in patients with T2D: a randomized placebo-controlled clinical trial (SOBER II)
Sponsor Odense University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
[⁶⁸Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)
Sponsor Odense University Hospital
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
The headache-inducing effects of cilostazol in men and women with migraine without aura
Sponsor Syddansk Universitet (University of Southern Denmark)
- Start (EU)
- Latest update
- Estimated end
- Not reported
Beneficial effects of Amiloride on progression of Chronic Kidney Disease: A-CKD
Sponsor Odense University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Odense University Hospital?
The 2026-10-09 snapshot links Odense University Hospital to 92 distinct CTIS trials. Recorded services include Clinical monitoring, Safety reporting & pharmacovigilance, Electronic data capture, Data management, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Odense University Hospital?
The most frequently recorded therapeutic areas are Haematological Malignancies, Endocrinology, Gastroenterology, Musculoskeletal. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Odense University Hospital conducted?
The linked trials record locations in 25 countries, including Denmark, Sweden, Norway, Finland, Germany. These are trial locations, not confirmed office locations or countries where Odense University Hospital delivered services.
What can this page tell me about Odense University Hospital's trial experience?
Browse 92 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Odense University Hospital. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Odense University Hospital